- Home
- RXST vs BEAM Comparison
RXST vs BEAM Comparison
Compare RXST & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- BEAM
- Stock Information
- Founded
- RXST 1997
- BEAM 2017
- Country
- RXST United States
- BEAM United States
- Employees
- RXST N/A
- BEAM N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXST Health Care
- BEAM Health Care
- Exchange
- RXST Nasdaq
- BEAM Nasdaq
- Market Cap
- RXST 2.0B
- BEAM 1.9B
- IPO Year
- RXST 2021
- BEAM 2020
- Fundamental
- Price
- RXST $45.08
- BEAM $24.05
- Analyst Decision
- RXST Strong Buy
- BEAM Buy
- Analyst Count
- RXST 8
- BEAM 11
- Target Price
- RXST $61.63
- BEAM $45.90
- AVG Volume (30 Days)
- RXST 663.3K
- BEAM 1.3M
- Earning Date
- RXST 11-07-2024
- BEAM 11-05-2024
- Dividend Yield
- RXST N/A
- BEAM N/A
- EPS Growth
- RXST N/A
- BEAM N/A
- EPS
- RXST N/A
- BEAM N/A
- Revenue
- RXST $128,293,000.00
- BEAM $349,643,000.00
- Revenue This Year
- RXST $60.19
- BEAM N/A
- Revenue Next Year
- RXST $34.96
- BEAM $6.04
- P/E Ratio
- RXST N/A
- BEAM N/A
- Revenue Growth
- RXST 67.52
- BEAM 328.73
- 52 Week Low
- RXST $27.07
- BEAM $20.84
- 52 Week High
- RXST $66.54
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- RXST 40.32
- BEAM 46.67
- Support Level
- RXST $43.85
- BEAM $21.46
- Resistance Level
- RXST $55.57
- BEAM $32.29
- Average True Range (ATR)
- RXST 2.46
- BEAM 2.04
- MACD
- RXST -0.68
- BEAM 0.19
- Stochastic Oscillator
- RXST 26.84
- BEAM 23.92
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.